Skip to main content

Simulations Plus Releases ADMET Predictor® (X.2)

Industry-driven enhancements further establish ADMET Predictor® as the preferred platform for discovery PBPK simulations

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has released version 10.2 of its flagship machine learning modeling platform, ADMET Predictor®. The new release will be marketed as APX.2.

Key enhancements in APX.2 include:

  • New capabilities in the High Throughput Pharmacokinetic (HTPK) Simulation Module which integrates machine learning and physiologically based pharmacokinetic (PBPK) technologies to guide lead selection
    • New intravenous (IV) bolus route of administration to complement oral dosing options
    • Multi-dosing for more complex administration regimens
    • Plasma concentration versus time curve overlay for easy comparison across compounds
    • Additional options for dose optimization to support universal safety and efficacy definitions
    • Dose optimization available through the MedChem Designer™ interface for real-time evaluation
  • Enhanced mutagenic risk rules which improve accuracy for the standard Ames mutagenicity assay
  • Extended software parallelization to significantly improve performance for cheminformatic tasks
  • Upgraded command line options to automate common applications of the software
  • Improved user experience with added options to customize spreadsheet displays

Dr. David Miller, vice president of ADMET cheminformatics, said: “APX.2 enhances the industry-leading discovery PBPK modeling capabilities within ADMET Predictor and cements the program as the premier environment for ADMET property prediction modeling. The R&D collaborations with our large pharmaceutical partner established the functionality requirements in the HTPK Simulation Module necessary to bridge communication between discovery and early development, and the new options for implementation provide the flexibility needed to fit almost any company’s internal workflow processes.”

“With capabilities to perform time-dependent mechanistic PK simulations at the rate of over 100 compounds per second, the exploratory nature of our discovery PBPK platform takes on its full meaning as it is deployed in pharmaceutical and biotechnology companies worldwide,” added Dr. Eric Jamois, director for key accounts and strategic alliances. “The accelerated growth in the ADMET Predictor product line revenue in 2QFY21 reflects this increased adoption, and we look forward to the positive momentum continuing as APX.2 is rolled out to the global user community.”

About Simulations Plus, Inc.

Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With our subsidiaries, Cognigen, DILIsym Services, and Lixoft, we offer solutions which bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, consumer goods companies and regulatory agencies worldwide. For more information, visit our website at Follow us on Twitter | Read our Environmental, Social, and Governance (ESG) Report.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.